Q-omics provides the consensus-scored RETSAT profile across patient tissues and cancer cell-line models. RETSAT expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RETSAT is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, RETSAT protein abundance shows 22,303 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, COAD, and LSCC as cancer lineages where RETSAT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RETSAT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RETSAT survival associations across molecular data types. RETSAT RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RETSAT RNA expression–survival associations across cancer types. High RETSAT expression shows unfavorable associations in SKCM, BLCA, LGG, UVM and ACC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RETSAT RNA expression.
This table summarizes RETSAT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 8. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RETSAT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RETSAT shows lower tumor expression in COAD, THCA, BRCA, READ, LUSC and KICH. The COAD box plot shows higher RETSAT RNA expression in normal versus tumor tissue (log2 FC = −1.885, t-test p < 0.001).
This table shows molecular features associated with RETSAT in patient tissues and cancer cell lines. In patient samples, RETSAT shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RETSAT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
